---
title: "A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients with Early Parkinson's Disease"
euct_id: 2022-502207-30-01
phase: Phase 4
status: Completed
sponsor: Clinuvel Europe Limited
canonical_url: "https://parkinsonspathways.com/trials/eu/2022-502207-30-01"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2022-502207-30-01"
ctis_last_updated: "2025-11-22T02:34:45.135853903"
source: EU Clinical Trials Information System (CTIS)
---
# A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients with Early Parkinson's Disease

**EU CT Number:** [2022-502207-30-01](https://euclinicaltrials.eu/ctis-public/view/2022-502207-30-01)

## Key Facts

- **Phase:** Phase 4
- **Status:** Completed
- **Sponsor:** Clinuvel Europe Limited
- **Start Date:** 2024-05-01
- **Completion Date:** 2025-01-01
- **Conditions:** Parkinson's Disease, Nervous system disorders, Parkinson's disease and parkinsonism, Disease Parkinson's
- **Interventions:** PRENUMBRA

## Member States

Trial is authorized in 1 member state: Spain.

## Sites (1)

- Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda, Majadahonda, Spain

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Parkinson's Disease; Nervous system disorders; Parkinson's disease and parkinsonism; Disease Parkinson's
Age groups: elderly 65+, adults 18-64
Sex: male, female

Period: Phase IIa Early Parkinson's Disease Study
A phase IIa, open label study
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2022-502207-30-01*  
*HTML version: https://parkinsonspathways.com/trials/eu/2022-502207-30-01*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2022-502207-30-01*